Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Lancet. Infectious Diseases (Print)

• Publication date

  2003-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1473-3099(03)00514-0PMID 12560191
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pneumococcal polysaccharide vaccine.

  2004cited by this paper
• Validation of immunoglobulin G enzyme-linked immunosorbent assay for antibodies to pneumococcal surface adhesin A in the diagnosis of pneumococcal pneumonia among adults in Kenya.

  2002cited by this paper
• Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults.

  2002cited by this paper
• Comparison between cohorts vaccinated and unvaccinated against influenza and pneumococcal infection

  2002cited by this paper
• The prevention of pneumococcal disease by vaccines: promises and challenges.

  2001cited by this paper
• Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia.

  2001cited by this paper
• Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials.

  2001cited by this paper
• Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

  2001cited by this paper
• Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps.

  2000cited by this paper
• Ten-year review of invasive pneumococcal diseases in children and adults from Uruguay: clinical spectrum, serotypes, and antimicrobial resistance.

  2000cited by this paper
• Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.

  2000cited by this paper
• 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.

  2000cited by this paper
• Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials

  2000cited by this paper
• The role of randomization in clinical studies: myths and beliefs.

  1999cited by this paper
• The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease.

  1999cited by this paper
• Safety of revaccination with pneumococcal polysaccharide vaccine.

  1999cited by this paper
• Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older.

  1999cited by this paper
• The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease.

  1999cited by this paper
• Determination of Antibody Responses of Elderly Adults to All 23 Capsular Polysaccharides after Pneumococcal Vaccination

  1999cited by this paper
• Clinical effectiveness of pneumococcal vaccine. Meta-analysis.

  1999cited by this paper
• Serotype distribution and prevalence of resistance to benzylpenicillin in three representative populations of Streptococcus pneumoniae isolates from the coast of Kenya.

  1998cited by this paper
• Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group.

  1998cited by this paper
• Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.

  1997cited by this paper
• Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial.

  1997cited by this paper
• Influenza surveillance--United States, 1992-93 and 1993-94.

  1997cited by this paper
• Side effects associated with pneumococcal vaccination.

  1997cited by this paper
• Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  1997cited by this paper
• Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease.

  1996cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis.

  1995cited by this paper
• Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study.

  1995cited by this paper
• Is there any connection between a second pneumonia shot and hospitalization among Medicare beneficiaries?

  1995cited by this paper
• Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials.

  1994cited by this paper
• Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations.

  1993cited by this paper
• Estimating the effects of misclassification.

  1993cited by this paper
• Bacterial infections of humans: epidemiology and control.

  1993cited by this paper
• Can meta-analyses be trusted?

  1991cited by this paper
• The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

  1991cited by this paper
• The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly

  1988cited by this paper
• The clinical effectiveness of pneumococcal vaccine in the elderly.

  1988cited by this paper
• Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease.

  1987cited by this paper
• Inefficacy of pneumococcal vaccine in a high-risk population.

  1987cited by this paper
• Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study.

  1987cited by this paper
• Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study.

  1986cited by this paper
• Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma.

  1986cited by this paper
• Pneumococcal vaccine efficacy in selected populations in the United States.

  1986cited by this paper
• [Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions].

  1985cited by this paper
• When was a "negative" clinical trial big enough? How many patients you needed depends on what you found.

  1985cited by this paper
• Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials?

  1984cited by this paper
• A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections.

  1984cited by this paper
• Pneumococcal vaccine: clinical efficacy and effectiveness.

  1982cited by this paper
• An epidemiologic approach to pneumococcal disease.

  1981cited by this paper
• A method for assessing the quality of a randomized control trial.

  1981cited by this paper
• Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine.

  1980cited by this paper
• Pneumococcal Disease after Pneumococcal Vaccination

  1980cited by this paper
• The assessment of pneumococcal vaccine.

  1980cited by this paper
• IMMUNISATION WITH A POLYVALENT PNEUMOCOCCAL VACCINE: Reduction of Adult Respiratory Mortality in a New Guinea Highlands Community

  1977cited by this paper
• Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974

  1977cited by this paper
• Protective efficacy of pneumococcal polysaccharide vaccines.

  1977cited by this paper
• Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines.

  1977cited by this paper
• Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community.

  1977cited by this paper
• Prevention of pneumococcal pneumonia by vaccination.

  1976cited by this paper
• Bacteriologic diagnosis of acute pneumonia. Comparison of sputum, transtracheal aspirates, and lung aspirates.

  1976cited by this paper
• Spread of Streptococcus pneumoniae in families. II. Relation of transfer of S. pneumoniae to incidence of colds and serum antibody.

  1975cited by this paper
• Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types.

  1975cited by this paper
• PNEUMONIA IN OLD AGE: Active Immunization Against Pneumonia with Pneumococcus Polysaccharide; Results of a Six Year Study

  1947cited by this paper

• Changes in the incidence, viral coinfection pattern and outcomes of pneumococcal hospitalizations during and after the COVID-19 pandemic

  2025cites this paper
• The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study.

  2024cites this paper
• A Trivalent Live Vaccine Elicits Cross-Species Protection Against Acute Otitis Media in a Murine Model

  2024cites this paper
• Hospitalisation outcomes in pneumococcal-vaccinated versus -unvaccinated patients with exacerbation of COPD: results from the HOPE COPD Study

  2023cites this paper
• Review on Pneumococcal Infection in Children

  2021cites this paper
• Skin and soft tissue infections

  2021cites this paper
• Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease

  2020influential citation
• CbpM and CbpG of Streptococcus Pneumoniae Elicit a High Protection in Mice Challenged with a Serotype 19F Pneumococcus.

  2019cites this paper
• Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older.

  2018cites this paper
• Discrepant serological assays for Pneumococcus in renal transplant recipients – a prospective study

  2017cites this paper
• Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

  2017cites this paper
• Involvement of Zizimin2/3 in the age-related defect of peritoneal B-1a cells as a source of anti-bacterial IgM

  2017cites this paper
• Community-acquired Staphylococcus aureus bacteremia: Studies of risk and prognosis with special attention to diabetes mellitus and chronic heart failure.

  2017cites this paper
• Evolution over a 15-year period of the clinical characteristics and outcomes of critically ill patients with severe community-acquired pneumonia.

  2016cites this paper
• Vaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccine

  2016cites this paper
• Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes

  2016cites this paper
• Hajj vaccinations-facts, challenges, and hope.

  2016cites this paper
• Pneumococcal pep27 mutant immunization stimulates cytokine secretion and confers long-term immunity with a wide range of protection, including against non-typeable strains.

  2016cites this paper
• Current Perspectives for Antipneumococcal Vaccination in Patients with Chronic Obstructive Pulmonary Disease

  2016cites this paper
• Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

  2015cites this paper
• [Pneumococcal infections: Appraisal and perspectives in terms of adult vaccination].

  2015cites this paper
• Vaccines for the Prevention of Pneumococcal

  2015cites this paper
• The epidemiology of infections among older people with diabetes mellitus and chronic kidney disease

  2015cites this paper
• 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults

  2015cites this paper
• Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial

  2015cites this paper
• Vaccines for the Prevention of Pneumococcal Disease.

  2015cites this paper
• Hypertension Management and Antihypertensive Withdrawal--A Perspective.

  2015cites this paper
• Pneumokokkenziekte

  2014cites this paper
• Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.

  2014cites this paper
• Chronic helminth infections impair pneumococcal vaccine responses.

  2014cites this paper
• Epidemiología de la neumonía adquirida en la comunidad

  2013cites this paper
• On-line prediction of the feeding phase in high-cell density cultivation of rE. coli using constructive neural networks

  2013cites this paper
• A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media

  2013cites this paper
• Development of improved diagnostic testing methods for invasive pneumococcal disease

  2013cites this paper
• Preventing Pneumococcal Disease in the Elderly

  2013cites this paper
• Vaccine-Preventable Disease

  2013cites this paper
• THE IMPACT OF HIV INFECTION ON COLONIZATION AND SEROEPIDEMIOLOGY OF STREPTOCOCCUS PNEUMONIAE AMONG ZAMBIAN WOMEN

  2013cites this paper
• Serotype Distribution in Non-Bacteremic Pneumococcal Pneumonia: Association with Disease Severity and Implications for Pneumococcal Conjugate Vaccines

  2013cites this paper
• Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines

  2012cites this paper
• Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany

  2012cites this paper
• Vaccination Recommendations for the Hematology and Oncology and Post–Stem Cell Transplant Populations

  2012cites this paper
• Economic Aspects of Pneumococcal Pneumonia

  2012cites this paper
• Vaccination anti-pneumococcique : état des lieux et perspectives

  2012cites this paper
• La pneumonie du patient âgé

  2012cites this paper
• Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview

  2012cites this paper
• Active Immunization with Pneumolysin versus 23-Valent Polysaccharide Vaccine for Streptococcus pneumoniae Keratitis.

  2011cites this paper
• Universal protein vaccines against Neisseria meningitidis serogroup B, Streptococcus pneumoniae and influenza

  2011cites this paper
• The role of antibodies against S. pneumoniae vaccine antigens in neutralizing colonization and invasion of human epithelial cells

  2011cites this paper
• IN-VITRO AND IN-VIVO EXPRESSION ANALYSIS OF PNEUMOCOCCAL VACCINE CANDIDATES : PILUS-1 COMPONENTS

  2011cites this paper
• Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.

  2011cites this paper
• A brief guide to pneumococcal vaccination

  2011cites this paper
• Colonisation-induced protection against Streptococcus pneumoniae disease

  2011cites this paper
• Genetic characterisation of Streptococcus pneumoniae serotype 1 isolates in relation to invasiveness.

  2010cites this paper
• [23-valent pneumococcal vaccine. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society: February 2010].

  2010cites this paper
• Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older

  2010cites this paper
• Revista chilena de infectología versão impressa ISSN 0716-1018

  2010cites this paper
• Declaración del Comité Consultivo de Inmunizaciones de la Sociedad Chilena de Infectología acerca de la eficacia de la vacuna anti-neumocóccica 23 valente en el adulto mayor: Febrero 2010

  2010cites this paper
• Rationale and design of the CAPAMIS study: Effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke

  2010cites this paper
• Clinical Features of Invasive Pneumococcal Disease in Korea

  2010cites this paper
• Vaccin anti-pneumococcique chez l'adulte: comparaison des recommandations et discussion de son intérêt

  2010influential citation
• Management of novel influenza epidemics in Singapore: consensus recommendations from the Hospital Influenza Workgroup (Singapore).

  2009cites this paper
• Efficacy of pneumococcal vaccination in adults: a meta-analysis

  2009cites this paper
• Vaccinate your child and save its grandparents from a heart attack? Current perspectives in antipneumococcal vaccination

  2009cites this paper
• Diagnosis and prognosis of patients with community- acquired bacteremia

  2009cites this paper
• Diversity of pneumococcal surface protein A (PspA) among prevalent clones in Spain

  2009cites this paper
• Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.

  2009cites this paper
• “Incidence of and Outcomes Associated With Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention” Jerome Chambers - “Genetic Alterations Associated with Cryptorchidism” Wanda Averhart - “Clinical trial: A Multistrain Probiotic Preparation Significa

  2009cites this paper
• Childhood Bacterial Respiratory Diseases: Past, Present, and Future

  2009cites this paper
• Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions.

  2009cites this paper
• Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention.

  2009cites this paper
• Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo.

  2009cites this paper
• Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD

  2009cites this paper
• Pneumococcal Serotypes and Mortality following Invasive Pneumococcal Disease: A Population-Based Cohort Study

  2009cites this paper
• Obesity, diabetes and hospitalization with pneumonia

  2009cites this paper
• Increasing Hospital Admissions for Pneumonia, England

  2008cites this paper
• Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study.

  2008cites this paper
• Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies

  2008cites this paper
• Bacterial Pneumonia and Pandemic Influenza Planning

  2008cites this paper
• Impact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian women.

  2008cites this paper
• Is the pneumococcal polysaccharide vaccine effective in preventing pneumonia?

  2008cites this paper
• Patients with Chronic Obstructive Pulmonary Disease

  2008cites this paper
• History of Pneumococcal Immunization

  2008cites this paper
• Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults.

  2008cites this paper
• [Pneumococcal vaccination: expected benefits in adults].

  2007cites this paper
• The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine.

  2007cites this paper
• Pneumococcal vaccination in adults: recommendations, trends, and prospects.

  2007cites this paper
• Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.

  2007cites this paper
• [Pneumococcal vaccination in the over-65 population].

  2007cites this paper
• Pneumococcal Capsular Polysaccharide Vaccine-Mediated Protection against Serotype 3 Streptococcus pneumoniae in Immunodeficient Mice

  2007cites this paper
• Pneumococcal bacteraemia in Belgium (1994 2004): the pre-conjugate vaccine era.

  2007cites this paper
• Identification of a human immunodominant B-cell epitope within the immunoglobulin A1 protease of Streptococcus pneumoniae

  2007cites this paper
• THE SCIENTIFIC PANEL ON VACCINES AND IMMUNISATION

  2007cites this paper
• Vaccination antipneumococcique : bénéfices attendus chez l'adulte

  2007cites this paper
• Vacunación antineumocócica en la población mayor de 65 años

  2007cites this paper
• ANTI-PROTEINASE 3 (PR3) ANTIBODIES UTILISE INNATE SIGNALLING PATHWAYS THAT LEAD TO INFLAMMATION

  2007cites this paper
• Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries

  2007cites this paper
• Advances in Pneumococcal Vaccines

  2007cites this paper
• VACCINATIONS | Viral

  2006cites this paper
• Characteristics and predictors for non-vaccination with PPV in the elderly population.

  2006cites this paper
• Polysaccharide pneumococcal vaccination: new evidence

  2006cites this paper